Alan B. Lancz & Associates, Inc. Bristol Myers Squibb CO Transaction History
Alan B. Lancz & Associates, Inc.
- $98.1 Million
- Q2 2025
A detailed history of Alan B. Lancz & Associates, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Alan B. Lancz & Associates, Inc. holds 6,750 shares of BMY stock, worth $294,232. This represents 0.32% of its overall portfolio holdings.
Number of Shares
6,750
Previous 6,750
-0.0%
Holding current value
$294,232
Previous $411,000
24.09%
% of portfolio
0.32%
Previous 0.44%
Shares
9 transactions
Others Institutions Holding BMY
# of Institutions
2,667Shares Held
1.64BCall Options Held
22.4MPut Options Held
25.4M-
Vanguard Group Inc Valley Forge, PA195MShares$8.5 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$6.92 Billion0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY108MShares$4.71 Billion0.52% of portfolio
-
State Street Corp Boston, MA94.7MShares$4.13 Billion0.17% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA70.8MShares$3.09 Billion0.59% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $92.7B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...